We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




European Nonprofit to Focus on Personalized Medicine and Diagnostics

By LabMedica International staff writers
Posted on 09 Nov 2009
A nonprofit launched in Europe will focus on promoting and harmonizing personalized medicine and implementing "high value" diagnostics across the continent.

The European Personalized Medicine Diagnostics Association (EPEMED; Nantes, France), a membership association formed in August 2009 as a not-for-profit organization, will provide a platform for harmonization in the development and implementation of value-based diagnostics across Europe, to make personalized medicine a reality. More...
Personalized Medicine refers to the use of a person's clinical, genetic, genomic, and environmental information to select more precisely and accurately treatment for each individual patient. Its aims are to improve care and lower costs.

The central goals of EPEMED are to move personalized medicine forward throughout Europe through targeted education, idea sharing, and business models. The group plans to create joint programs with other international personalized medicine organizations, and to offer opinions on policies related to the field.

EPEMED appointed experts in the field of personalized medicine and molecular diagnostics as its founding board of directors. They include executives from Ipsogen (Marseilles, France), Genzyme Genetics (Cambridge, MA, USA), the Personalized Medicine Coalition (Washington, DC, USA), Theranostics (Rockville, MD, USA), and Novartis Molecular Diagnostics (East Hanover, NJ, USA), as well as from academic and institutional researchers, other businesses, and patient advocacy groups.

"The next few years will see deep changes in medical care due to the development of breakthrough innovations in the field of molecular diagnostics that will help clinicians in better treating their patients," Alain Huriez, founder and chairman of EPEMED, said in a statement. "It is our responsibility to make sure that these innovations will be made available to European patients and as a result, to make Europe an attractive place for innovations, financial and industrial investments in the area of personalized medicine diagnostics."

Related Links:

European Personalised Medicine Diagnostics Association
Ipsogen
Genzyme Genetics
Personalized Medicine Coalition
Theranostics
Novartis Molecular Diagnostics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.